DDInter1042 DDInter817
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
Gilteritinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Gilteritinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Gilteritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentamidine
Gilteritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deutetrabenazine
Gilteritinib {u} may lead to a major life threatening interaction when taken with {v} Dronedarone
Gilteritinib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Gilteritinib may lead to a major life threatening interaction when taken with Dronedarone
Gilteritinib may lead to a major life threatening interaction when taken with Troleandomycin